AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9559764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume or inspired PCO2 modification to alter PaCO2 levels
Number of subjects: 36
Study 9559764 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved CBF response to CO2
Number of subjects: 36
Study 9559764 — intervention group
Group type: COMPARATOR
Intervention: Transcranial Doppler ultrasonography
Number of subjects: 36
Study 8180514 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 2644337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60-80 mg/day
Number of subjects: 14
Study 2644337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 4753715 — intervention group
Group type: EXPERIMENTAL
Intervention: High Density Rolling Stock under different densities and environmental constraints
Number of subjects: 0
Study 30375910 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD)
Number of subjects: 0
Study 30375910 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
Number of subjects: 0
Study 28263650 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive (SE) psychodynamic treatment
Number of subjects: 0
Study 25212601 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conformal radiation therapy (3D‐CRT, 70 Gy/35 fractions)
Number of subjects: 129
Study 25212601 — intervention group
Group type: COMPARATOR
Intervention: Intensity‐modulated radiation therapy (IMRT, 76 Gy/38 fractions)
Number of subjects: 129
Study 25212601 — intervention group
Group type: EXPERIMENTAL
Intervention: APC for Grade 2 or 3 rectal bleeding
Number of subjects: 129
Study 25212601 — intervention group
Group type: EXPERIMENTAL
Intervention: V65 ≥ 17%
Number of subjects: 129
Study 23444424 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth
Number of subjects: 3230
Study 23444424 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3230
Study 21443965 — intervention group
Group type: EXPERIMENTAL
Intervention: ACWY-TT + MMRV
Number of subjects: 1000
Study 21443965 — intervention group
Group type: EXPERIMENTAL
Intervention: ACWY-TT
Number of subjects: 1000
Study 21443965 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV
Number of subjects: 1000
Study 21443965 — intervention group
Group type: COMPARATOR
Intervention: MenC-CRM(197)
Number of subjects: 1000
Study 18193919 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg)
Number of subjects: 10
Study 18193919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 10
Study 18193919 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) and Ibuprofen (400 mg) concomitantly
Number of subjects: 10
Study 19462544 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (aerobic exercise)
Number of subjects: 25
Study 19462544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 12540598 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg b.i.d.)
Number of subjects: 41
Study 12540598 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g b.i.d.)
Number of subjects: 41
Study 10757453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 18
Study 10757453 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal
Number of subjects: 18
Study 9013382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen (Seractil: S(+)‐ibuprofen)
Number of subjects: 0
Study 1354274 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg daily)
Number of subjects: 740
Study 1354274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study 6355055 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream
Number of subjects: 30
Study 31701238 — intervention group
Group type: EXPERIMENTAL
Intervention: IG-MA (remobilization strategy in a memory clinic)
Number of subjects: 81
Study 31701238 — intervention group
Group type: COMPARATOR
Intervention: KG1-AGR (standard remobilization unit)
Number of subjects: 81
Study 31701238 — intervention group
Group type: COMPARATOR
Intervention: KG2-PWH (care homes)
Number of subjects: 81
Study 30672128 — intervention group
Group type: EXPERIMENTAL
Intervention: mirogabalin 30 mg/day
Number of subjects: 834
Study 30672128 — intervention group
Group type: EXPERIMENTAL
Intervention: mirogabalin 20 mg/day
Number of subjects: 834
Study 30672128 — intervention group
Group type: EXPERIMENTAL
Intervention: mirogabalin 15 mg/day
Number of subjects: 834
Study 30672128 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 834
Study 26260325 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (TH) intervention
Number of subjects: 447
Study 26260325 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 447
Study 24662235 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Periodization (LP)
Number of subjects: 13
Study 24662235 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (DUP)
Number of subjects: 13
Study 24461313 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil (0.5, 1, 2, or 4 g/day)
Number of subjects: 300
Study 24461313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 300
Study 22012469 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% hyaluronan gel
Number of subjects: 14
Study 22012469 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 14
Study 19302393 — intervention group
Group type: EXPERIMENTAL
Intervention: New cross-linked collagen membrane (VN)
Number of subjects: 54
Study 19302393 — intervention group
Group type: COMPARATOR
Intervention: Native collagen membrane (BG)
Number of subjects: 54
Study 16914226 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavor enhancement (700 mg)
Number of subjects: 83
Study 16914226 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) (300 mg)
Number of subjects: 83
Study 16914226 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavor plus MSG
Number of subjects: 83
Study 16914226 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 15573070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia (group B)
Number of subjects: 1440
Study 15573070 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (group C)
Number of subjects: 1440
Study 11894974 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ACTH [1‐24] (0.1 microg, 0.5 microg, 1.0 microg per 1.73 m2)
Number of subjects: 42
Study 11894974 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ACTH [1‐24] (250 microg, 60-minute HDT)
Number of subjects: 42
Study 11894974 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-h infusion test (250 microg ACTH [1‐24] at a constant rate over 8 h)
Number of subjects: 42
Study 11894974 — intervention group
Group type: COMPARATOR
Intervention: Insulin hypoglycaemia test (IHT)
Number of subjects: 42
Study 11894974 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ACTH [1‐24] (0.1 microg, 0.5 microg, 1.0 microg)
Number of subjects: 42
Study 11894974 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ACTH [1‐24] (HDT)
Number of subjects: 42
Study 9452545 — intervention group
Group type: COMPARATOR
Intervention: In-office 35% carbamide peroxide bleaching product in 2 visits of 15 minutes each
Number of subjects: 20
Study 9452545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination at-home and in-office system with a 15% carbamide peroxide at-home bleaching agent
Number of subjects: 20
Study 8198938 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg three times daily)
Number of subjects: 149
Study 8198938 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg three times daily)
Number of subjects: 149
Study 8198938 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 149
Study 8198938 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 149
Study 3141537 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (topical)
Number of subjects: 0
Study 3141537 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (topical)
Number of subjects: 0
Study 3141537 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (topical)
Number of subjects: 0
Study 3141537 — intervention group
Group type: EXPERIMENTAL
Intervention: N-hydroxy-arachidonamide (AH) (topical)
Number of subjects: 0
Study 3141537 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenidone (topical)
Number of subjects: 0
Study 3141537 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenidone with ionomycin (topical)
Number of subjects: 0
Study 28534247 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent motivation for PA
Number of subjects: 148
Study 28534247 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritative parenting
Number of subjects: 148
Study 28534247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangible support
Number of subjects: 148
Study 28534247 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 148
Study 26746631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 350
Study 26746631 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 350
Study 25470086 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable (LAI) antipsychotics
Number of subjects: 0
Study 25470086 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotic regimens
Number of subjects: 0
Study 23841729 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA plus arsenic trioxide
Number of subjects: 156
Study 23841729 — intervention group
Group type: COMPARATOR
Intervention: ATRA plus chemotherapy
Number of subjects: 156
Study 20444251 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 389
Study 20444251 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D index
Number of subjects: 389
Study 20444251 — intervention group
Group type: COMPARATOR
Intervention: EQ VAS, EQ-5D index
Number of subjects: 389
Study 17173719 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored outreach intervention plus usual care
Number of subjects: 348
Study 17173719 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 348
Study 15333602 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced provision of three courses of emergency contraception (EC)
Number of subjects: 1030
Study 15333602 — intervention group
Group type: COMPARATOR
Intervention: Control group obtaining each course of EC from clinic
Number of subjects: 1030
Study 15333602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 1030
Study 11407439 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol 6‐18 mg/day for 3 weeks
Number of subjects: 30
Study 9510490 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma testosterone (TTT) levels in patients with CAD (252+/‐125 ng/ml)
Number of subjects: 201
Study 9510490 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma testosterone (TTT) level
Number of subjects: 201
Study 7812682 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-59227 (240 mg oral dose)
Number of subjects: 8
Study 7812682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7812682 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-59227
Number of subjects: 8
Study 3042485 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 16
Study 3042485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29289496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation with 4 months of sitting-specific motivational support
Number of subjects: 36
Study 29289496 — intervention group
Group type: COMPARATOR
Intervention: Ergonomic focused motivational support
Number of subjects: 36
Study 26808666 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 210
Study 26808666 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills containing drospirenone
Number of subjects: 210
Study 26808666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 25111196 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsterile gloves after hand hygiene (group A)
Number of subjects: 120
Study 25111196 — intervention group
Group type: COMPARATOR
Intervention: Hand hygiene alone (group B)
Number of subjects: 120
Study 24330707 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan
Number of subjects: 129
Study 24330707 — intervention group
Group type: COMPARATOR
Intervention: Rizatriptan
Number of subjects: 129
Study 20666271 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD (n = 507)
Number of subjects: 82
Study 20666271 — intervention group
Group type: COMPARATOR
Intervention: AAD (n = 509)
Number of subjects: 82
Study 17947349 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐BMDA
Number of subjects: 38
Study 17947349 — intervention group
Group type: COMPARATOR
Intervention: MBIDS
Number of subjects: 38
Study 16634384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 77
Study 16634384 — intervention group
Group type: COMPARATOR
Intervention: Ametop cream
Number of subjects: 77
Study 14978593 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 200
Study 14978593 — intervention group
Group type: COMPARATOR
Intervention: Control (no metoprolol)
Number of subjects: 200
Study 11581049 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness measurement using ultrasonic pachymeters
Number of subjects: 1301
Study 11581049 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness measurement in African American subjects
Number of subjects: 1301
Study 11581049 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness measurement in white subjects
Number of subjects: 1301
Study 11581049 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with greater mean central corneal thickness
Number of subjects: 1301
Study 9732910 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin supplementation
Number of subjects: 0
Study 9732910 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 9732910 — intervention group
Group type: COMPARATOR
Intervention: Antioxidants
Number of subjects: 0
Study 9732910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8151317 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiagent chemotherapy and cranial irradiation
Number of subjects: 220
Study 8151317 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of methotrexate and cytarabine (ara‐c)
Number of subjects: 220
Study 8151317 — intervention group
Group type: COMPARATOR
Intervention: Cranial irradiation (18 Gy for SR, 24 Gy for HR and VHR)
Number of subjects: 220
Study 3047215 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone 21‐phosphate 30 mg (PP)
Number of subjects: 18
Study 3047215 — intervention group
Group type: COMPARATOR
Intervention: beclomethasone dipropionate 1 mg (BDP)
Number of subjects: 18
Study 30362889 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 50
Study 26925897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics educational intervention based on Transtheoretical Model (TTM) variables, conducted over four weeks.
Number of subjects: 82
Study 26925897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 82
Study 23426902 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release carbidopa-levodopa (IPX066)
Number of subjects: 27
Study 23426902 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release carbidopa-levodopa (IR CD-LD)
Number of subjects: 27
Study 23426902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (IPX066 and IR CD-LD)
Number of subjects: 27
Study 22101764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpramipexole (50, 150 or 300 mg d(‐1))
Number of subjects: 0
Study 22101764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpramipexole (50 mg d(‐1) or 300 mg d(‐1))
Number of subjects: 0
Study 22101764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19225038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination perindopril-indapamide
Number of subjects: 11140
Study 19225038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study 16988008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebola virus DNA vaccine (2 mg, 4 mg, or 8 mg)
Number of subjects: 26
Study 16988008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 14682408 — intervention group
Group type: EXPERIMENTAL
Intervention: BB genotype of eNOS gene
Number of subjects: 42
Study 14682408 — intervention group
Group type: EXPERIMENTAL
Intervention: NonBB genotypes of eNOS gene
Number of subjects: 42
Study 14682408 — intervention group
Group type: COMPARATOR
Intervention: ACE gene polymorphism
Number of subjects: 42
Study 10790932 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-directed 'healthy lifestyle' program
Number of subjects: 49
Study 10790932 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 49
Study 9310876 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDOGAIN treatment as an adjunct to modified widman flap (MWF) surgery
Number of subjects: 33
Study 9310876 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with MWF surgery
Number of subjects: 33
Study 9310876 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDOGAIN treatment
Number of subjects: 33
Study 9310876 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study 8147164 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel intracervical for Bishop score < 5
Number of subjects: 1472
Study 8147164 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal tablets for Bishop score between 5 and 8
Number of subjects: 1472
Study 8147164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion for Bishop score > 8
Number of subjects: 1472
Study 8147164 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of induction
Number of subjects: 1472
Study 8147164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical condition appropriate method of induction
Number of subjects: 1472
Study 3764227 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug
Number of subjects: 0
Study 3764227 — intervention group
Group type: COMPARATOR
Intervention: Old drug
Number of subjects: 0
Study 30795760 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin questionnaire in group A (home-based sleep test)
Number of subjects: 316
Study 30795760 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin questionnaire in group B (hospital-based polysomnography)
Number of subjects: 316
Study 30795760 — intervention group
Group type: COMPARATOR
Intervention: Berlin questionnaire compared to PSG
Number of subjects: 316
Study 30795760 — intervention group
Group type: COMPARATOR
Intervention: Berlin questionnaire compared to Embletta PDS
Number of subjects: 316
Study 30795760 — intervention group
Group type: COMPARATOR
Intervention: Area under the ROC curve based on PSG
Number of subjects: 316
Study 30795760 — intervention group
Group type: COMPARATOR
Intervention: Area under the ROC curve based on home Embletta
Number of subjects: 316
Study 28991766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided catheterization
Number of subjects: 400
Study 28991766 — intervention group
Group type: COMPARATOR
Intervention: Landmark method catheterization
Number of subjects: 400
Study 25611582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bariatric surgery physical activity intervention (PAI)
Number of subjects: 75
Study 25611582 — intervention group
Group type: COMPARATOR
Intervention: Standard pre‐surgical care (SC)
Number of subjects: 75
Study 25219986 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone acetate injected preoperatively into the masseter muscle
Number of subjects: 60
Study 25219986 — intervention group
Group type: COMPARATOR
Intervention: 40 mg methylprednisolone acetate injected postoperatively into the masseter muscle
Number of subjects: 60
Study 22964250 — intervention group
Group type: EXPERIMENTAL
Intervention: LFF571 single doses (25 mg, 100 mg, 400 mg, and 1,000 mg)
Number of subjects: 56
Study 22964250 — intervention group
Group type: EXPERIMENTAL
Intervention: LFF571 multiple doses (25 mg, 100 mg, or 200 mg every 6 h for 10 days)
Number of subjects: 56
Study 22964250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 19306963 — intervention group
Group type: EXPERIMENTAL
Intervention: Barusiban (0.3, 1, 3, or 10 mg)
Number of subjects: 163
Study 19306963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 17344656 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 60
Study 17344656 — intervention group
Group type: COMPARATOR
Intervention: No inhaled nitric oxide (no iNO)
Number of subjects: 60
Study 15125004 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy merging method
Number of subjects: 82
Study 15125004 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall-thickening analysis
Number of subjects: 82
Study 15125004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fuzzy merging and wall-thickening analysis
Number of subjects: 82
Study 15125004 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CAD scheme
Number of subjects: 82
Study 11453312 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (0.8 mg m(‐2) day(‐1) for 1 month, then 0.4 mg m(‐2) day(‐1) for 3 months)
Number of subjects: 21
Study 9744787 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension
Number of subjects: 1
Study 9744787 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study 8061853 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg/day
Number of subjects: 260